<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Filed Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) December 14, 2000
ILEX ONCOLOGY, INC.
------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware
----------------------------------------------
(State or Other Jurisdiction of Incorporation)
0-23413 94-3123681
------------------------ ---------------------------------
(Commission File Number) (IRS Employer Identification No.)
4545 Horizon Hill Blvd., San Antonio, Texas 78229
---------------------------------------- ----------
(Address of Principal Executive Offices) (Zip Code)
(210) 949-8200
----------------------------------------------------
(Registrant's Telephone Number, Including Area Code)
-------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
<PAGE> 2
Item 5. Other Events.
On December 14, 2000, ILEX Oncology, Inc. issued a press release
regarding the recommendations of the Oncologic Drugs Advisory Committee to the
U.S. Food and Drug Administration on CAMPATH(R). The press release is attached
hereto as Exhibit 99.1 and incorporated herein by reference. The foregoing
description is qualified by reference to such exhibit.
Item 7 (c). Exhibits.
Exhibit 99.1 Press Release dated December 14, 2000.
-2-
<PAGE> 3
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
ILEX ONCOLOGY, INC.
By /s/ Gregory L. Weaver
----------------------------------
Gregory L. Weaver
Vice President and Chief Financial
Officer
DATE: December 14, 2000
<PAGE> 4
INDEX TO EXHIBITS
<TABLE>
<CAPTION>
EXHIBIT
NUMBER DESCRIPTION
-------- -----------
<S> <C>
99.1 Press Release
</TABLE>
